功能性影像在多发性骨髓瘤中应用十五年:从起点到未来方向
本文综述功能性影像技术在多发性骨髓瘤中的应用现状与指南推荐。国际骨髓瘤工作组推荐全身低剂量CT为骨病诊断首选,MRI用于无其他骨髓瘤定义事件者,18F-FDG-PET/CT因结合形态与功能数据而成为标准影像技术并用于影像学微小残留病评估。IMPeTUs提出18F-FDG-PET/CT视觉描述评估与代谢反应标准化定义,扩散加权MRI在分期和疗效评估中结果 promising,英国指南将其视为18F-FDG-PET/CT的替代方案。
要点
- 国际骨髓瘤工作组推荐全身低剂量CT为骨病诊断首选影像技术。
- 18F-FDG-PET/CT因结合形态与功能数据成为标准影像技术,用于骨病灶检测、预后分层和疗效监测。
- 国际骨髓瘤工作组推荐18F-FDG-PET/CT用于影像学微小残留病评估。
核心结论
- 本综述总结了功能性影像技术在多发性骨髓瘤中的应用及其在推荐/指南中的整合,并讨论了该领域的潜在未来发展。
研究设计与样本
- 综述,总结当前关于功能性影像技术在多发性骨髓瘤中应用的知识及其在推荐/指南中的纳入情况。
主要发现
- 骨病是多发性骨髓瘤的标志性特征,几乎在所有患者病程中都会出现。
- 形态学影像技术对检测骨病至关重要,而功能性影像技术对于区分活动性与非活动性疾病及预后分层也具基础性作用。
- 国际骨髓瘤工作组目前推荐全身低剂量CT作为骨病诊断的首选影像技术,而磁共振成像推荐用于无进一步骨髓瘤定义事件的病例。
- 18F-FDG-PET/CT目前代表标准影像技术,因其结合形态学和功能数据,可检测骨病灶(替代全身低剂量CT)、进行预后分层和监测治疗反应。
- IMPeTUs提出了18F-FDG-PET/CT的视觉描述评估,并标准化定义了代谢反应。
关键数值与推荐
- 国际骨髓瘤工作组推荐全身低剂量CT作为骨病诊断的首选影像技术。
- 国际骨髓瘤工作组推荐磁共振成像用于无进一步骨髓瘤定义事件的病例。
- 国际骨髓瘤工作组推荐18F-FDG-PET/CT用于影像学微小残留病评估。
- 英国指南认为扩散加权MRI是18F-FDG-PET/CT的替代方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone disease represents a hallmark feature of multiple myeloma (MM), affecting nearly all patients during the disease course. Morphological imaging techniques play a crucial role in detecting bone disease, whereas functional ones are also fundamental for the differentiation of active from inactive disease and prognostic stratification. The International Myeloma Working Group (IMWG) currently recommends whole-body low-dose computed tomography (WBLDCT) as the first-choice imaging technique for the diagnosis of bone disease, whereas magnetic resonance imaging (MRI) is recommended in cases without further myeloma-defining events. However, 18F-fluorodeoxyglucose-positron emission tomography/CT (18F-FDG-PET/CT) currently represents the standard imaging technique, because it combines both morphological and functional data. Indeed, it allows detection of bone lesions (alternatively to WBLDCT), prognostic stratification, and monitoring of treatment response, being recommended by the IMWG for the assessment of imaging minimal residual disease. The IMPeTUs (Italian Myeloma criteria for PET Use) have proposed a visual descriptive assessment of 18F-FDG-PET/CT, with standardized definitions of metabolic responses. However, the use of further functional imaging techniques is being investigated, with diffusion-weighted (DW)-MRI being related to very promising results regarding both staging and response assessment, to the extent that myeloma response assessment and diagnosis system guidelines have recently proposed a standardization of acquisition, interpretation and reporting of this technique in MM, and the British guidelines consider DW-MRI an alternative to 18F-FDG-PET/CT. This review summarizes current knowledge on the use of functional imaging techniques in MM and their incorporation in recommendations/guidelines, and discusses potential future developments in this setting.
引用
- Zamagni E, Talarico M. Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going. Blood Adv. 2025. PMID: 40875592. doi:10.1182/bloodadvances.2024015686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。